<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PCH</journal-id>
<journal-id journal-id-type="hwp">sppch</journal-id>
<journal-title>World Journal for Pediatric and Congenital Heart Surgery</journal-title>
<issn pub-type="ppub">2150-1351</issn>
<issn pub-type="epub">2150-0136</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2150135113481042</article-id>
<article-id pub-id-type="publisher-id">10.1177_2150135113481042</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Off-Label Drug Use in a Single-Center Pediatric Cardiac Intensive Care Unit</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Maltz</surname>
<given-names>Lily A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2150135113481042">1</xref>
<xref ref-type="corresp" rid="corresp1-2150135113481042"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klugman</surname>
<given-names>Darren</given-names>
</name>
<degrees>MD, MMS</degrees>
<xref ref-type="aff" rid="aff1-2150135113481042">1</xref>
<xref ref-type="aff" rid="aff2-2150135113481042">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spaeder</surname>
<given-names>Michael C.</given-names>
</name>
<degrees>MD, MS</degrees>
<xref ref-type="aff" rid="aff2-2150135113481042">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wessel</surname>
<given-names>David L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-2150135113481042">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2150135113481042"><label>1</label>Department of Cardiology, Children’s National Medical Center, Washington, DC, USA</aff>
<aff id="aff2-2150135113481042"><label>2</label>Department of Critical Care, Children’s National Medical Center, Washington, DC, USA</aff>
<author-notes>
<corresp id="corresp1-2150135113481042">Lily A. Maltz, The Massachusetts General Hospital for Children, 55 Fruit Street, Boston, MA 02114, USA. Email: <email>Lily.maltz@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>3</issue>
<fpage>262</fpage>
<lpage>266</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>10</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>2</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">World Society for Pediatric and Congential Heart Surgery</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Background:</title>
<p>The frequency of off-label drug use and its association with morbidity and mortality in the cardiac intensive care unit (CICU) has not been previously studied.</p></sec>
<sec>
<title>Methods:</title>
<p>Patients less than 18 years of age admitted to the CICU from June to August 2008 were retrospectively identified. Patient demographics were collected for 30 days or until CICU discharge. Off-label drug use was defined as the prescription of a medication that lacked a labeled indication based on patient’s age as reported in the Micromedex drug database and electronic Physician’s Desk Reference.</p></sec>
<sec>
<title>Results:</title>
<p>Eighty-two patients were admitted to the CICU during the study period. In all, 40 (46%) patients were male; the median age was 10.6 months. Common diagnoses were left-to-right shunt lesions (20.7%) and single-ventricle lesions (20.7%), with an overall mortality of 2.4%. Of all drugs prescribed, 36% were off-label. In all, 94% of the patients received ≥1 drug off-label. The median number of drugs prescribed off-label was four. Patients receiving more than four off-label medications were younger, had longer CICU lengths of stay (median 9.5 vs 2 days, <italic>P</italic> &lt; .001), and increased ventilator days (median two vs one day, <italic>P</italic> &lt; .001).</p></sec> 
<sec>
<title>Conclusions:</title>
<p>Off-label drug use in the CICU is common. Frequency of use is likely higher in patients with a higher severity of illness. Further safety, efficacy, and pharmaceutical trials are warranted to optimize the use of these drugs to improve outcomes.</p></sec>
</abstract>
<kwd-group>
<kwd>congenital heart disease</kwd>
<kwd>off-label drugs</kwd>
<kwd>critical care</kwd>
<kwd>pediatrics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2150135113481042">
<title>Introduction</title>
<p>Congenital heart disease occurs in 1% of live births and is the most common type of birth defect.<sup>
<xref ref-type="bibr" rid="bibr1-2150135113481042">1</xref>
</sup> Advancements in the treatment for children with congenital heart disease have led to an increased number of specialized pediatric cardiac intensive care units (CICUs). Subsequently, improvements in both surgical and medical management of children with congenital and acquired cardiovascular disease have led to an increase in survival,<sup>
<xref ref-type="bibr" rid="bibr2-2150135113481042">2</xref>,<xref ref-type="bibr" rid="bibr3-2150135113481042">3</xref>
</sup> necessitating an increased need for therapeutic drug options. However, there is a paucity of pediatric evidence-based efficacy, safety, and dosing information on many commonly used drugs,<sup>
<xref ref-type="bibr" rid="bibr4-2150135113481042">4</xref>
</sup> and as a result, prescribing practice is often based on extrapolation from adult data and clinical experience.</p>
<p>Despite recent legislation that enhances pediatric drug-approval processes and increases incentives for industry-sponsored trials in children,<sup>
<xref ref-type="bibr" rid="bibr5-2150135113481042">5</xref>,<xref ref-type="bibr" rid="bibr6-2150135113481042">6</xref>
</sup> we suspect there continues to be significant off-label drug use in pediatric CICUs. The purpose of this study is to measure the frequency of off-label drug use and to correlate this with clinically important outcomes in a single-center pediatric CICU.</p>
</sec>
<sec id="section2-2150135113481042" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-2150135113481042">
<title>Patient Data</title>
<p>The Institutional Review Board of Children’s National Medical Center approved this study. We performed a retrospective cohort study identifying all patients younger than 18 years admitted to the Children’s National Medical Center CICU, a 13-bed CICU, between June 2008 and August 2008. Care is provided by a multidisciplinary team of intensivists, cardiologists, surgeons, anesthesiologists, nurse practitioners, nurses, respiratory care specialists, pharmacists, and nutritionists. Demographic data for each patient including mortality, CICU length of stay (LOS), and ventilator days were collected for 30 days or until CICU discharge. The patient age was defined as age on the date of admission to the CICU.</p>
</sec>
<sec id="section4-2150135113481042">
<title>Medication Data</title>
<p>All prescribed medications were recorded and classified into one of the following categories: antibiotics/antifungals, vasoactives, analgesics, sedatives and anesthetics, paralytic agents, diuretics, antiarrhythmics, antihypertensives, bronchodilators, steroids, gastrointestinal medications, anticoagulants/procoagulants/hemostatics, β-antagonists for heart failure, endocrine medications, and other medications. The Micromedex drug index and the electronic Physician’s Desk Reference were used to determine the off-label drug use. Off-label drug use was defined as a prescription of a drug for a patient younger than the age range defined by the drug label for any labeled indication. The following were excluded from analysis: flushes of sodium chloride 0.9% or heparin to maintain intravenous line patency, blood products, standard intravenous replacement solutions, and oxygen therapy.</p>
</sec>
<sec id="section5-2150135113481042">
<title>Statistical Analysis</title>
<p>Descriptive analysis was performed on demographic and diagnostic variables as well as off-label drug use. Patients were stratified by the number of off-label drugs received (greater than the median vs less than or equal to the median). Subgroup analyses were conducted on neonates, defined as patients aged ≤60 days on the day of admission. Continuous variables were compared using Wilcoxon rank sum testing. Categorical variables were compared using chi-square or Fisher exact testing as appropriate. Multivariate regression analyses were performed to assess the impact of off-label drug use on LOS, adjusting for potential confounders. Type-one error was set at 0.05. All calculations were performed using Stata/IC 10.1 (Stata Corporation, College Station, Texas) or SAS version 9.1 (SAS Institute, Cary, North Carolina).</p>
</sec>
</sec>
<sec id="section6-2150135113481042">
<title>Results</title>
<p>Demographic information of the study population is shown in <xref ref-type="table" rid="table1-2150135113481042">Table 1</xref>. During the study, 82 patients were admitted to the CICU; 38 (46.3%) males and 44 (53.7%) females with a median age of 10.6 months (intraquartile range [IQR] 38 days to 5 years). Diagnoses are shown in <xref ref-type="table" rid="table2-2150135113481042">Table 2</xref>; the most common diagnoses were left-to-right shunt lesions (20.7%) and single ventricle lesions (20.7%). The median CICU LOS was three days (IQR 1-9 days), and there were two (2.4%) mortalities.</p>
<table-wrap id="table1-2150135113481042" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of Demographic Characteristics.</p>
</caption>
<graphic alternate-form-of="table1-2150135113481042" xlink:href="10.1177_2150135113481042-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Number (% or IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Gender</td>
</tr>
<tr>
<td> Male</td>
<td>38 (46.3)</td>
</tr>
<tr>
<td> Female</td>
<td>44 (53.7)</td>
</tr>
<tr>
<td>Age, months</td>
<td>10.6 months (IQR 38 days to 5 years)</td>
</tr>
<tr>
<td> 0-2</td>
<td>26 (31.7)</td>
</tr>
<tr>
<td> 3-24</td>
<td>26 (31.7)</td>
</tr>
<tr>
<td> 25-60</td>
<td>9 (11.1)</td>
</tr>
<tr>
<td> ≥60</td>
<td>21 (25.6)</td>
</tr>
<tr>
<td>Length of stay, days</td>
<td>3 (IQR 1-9)</td>
</tr>
<tr>
<td> Non-neonate</td>
<td>2 (IQR 1-6)</td>
</tr>
<tr>
<td> Neonate</td>
<td>8.5 (IQR 4-20.5)</td>
</tr>
<tr>
<td colspan="2">Ventilator days, days</td>
</tr>
<tr>
<td> 0</td>
<td>19 (23.2)</td>
</tr>
<tr>
<td> 1</td>
<td>20 (24.4)</td>
</tr>
<tr>
<td> 2-4</td>
<td>24 (29.3)</td>
</tr>
<tr>
<td> 5-31</td>
<td>19 (23.2)</td>
</tr>
<tr>
<td colspan="2">Operative procedure/catheterization</td>
</tr>
<tr>
<td> Yes</td>
<td>66 (80.5)</td>
</tr>
<tr>
<td> No</td>
<td>16 (19.5)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2150135113481042">
<p>Abbreviation: IQR, intraquartile range.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-2150135113481042" position="float">
<label>Table 2.</label>
<caption>
<p>Diagnoses.</p>
</caption>
<graphic alternate-form-of="table2-2150135113481042" xlink:href="10.1177_2150135113481042-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left-to-right shunt lesions</td>
<td>17 (20.7)</td>
</tr>
<tr>
<td> Aorticopulmonary window</td>
<td>
</td>
</tr>
<tr>
<td> Patent ductus arteriosus</td>
<td>
</td>
</tr>
<tr>
<td> Atrial septal defect</td>
<td>
</td>
</tr>
<tr>
<td> VSD</td>
<td>
</td>
</tr>
<tr>
<td> Common atrioventricular canal</td>
<td>
</td>
</tr>
<tr>
<td> Anomalous pulmonary venous connection</td>
<td>
</td>
</tr>
<tr>
<td> Truncus arteriosus</td>
<td>
</td>
</tr>
<tr>
<td>Left ventricular outflow tract obstruction</td>
<td>9 (11.0)</td>
</tr>
<tr>
<td> Aortic, subaortic, and supravalvar aortic stenosis</td>
<td>
</td>
</tr>
<tr>
<td> Interrupted aortic arch</td>
<td>
</td>
</tr>
<tr>
<td> Coarctation of the aorta no VSD</td>
<td>
</td>
</tr>
<tr>
<td> Coarctation of the aorta with VSD</td>
<td>
</td>
</tr>
<tr>
<td>Right ventricular outflow tract obstruction</td>
<td>14 (17.1)</td>
</tr>
<tr>
<td> Tetralogy of fallot</td>
<td>
</td>
</tr>
<tr>
<td> Pulmonary atresia with intact ventricular septum</td>
<td>
</td>
</tr>
<tr>
<td> Pulmonary stenosis</td>
<td>
</td>
</tr>
<tr>
<td>Single ventricle lesions</td>
<td>17 (20.7)</td>
</tr>
<tr>
<td> Single left ventricle</td>
<td>
</td>
</tr>
<tr>
<td> Hypoplastic left heart syndrome</td>
<td>
</td>
</tr>
<tr>
<td> Other single right ventricle</td>
<td>
</td>
</tr>
<tr>
<td> Other single ventricle lesion</td>
<td>
</td>
</tr>
<tr>
<td>Other conotruncal lesions</td>
<td>11 (13.4)</td>
</tr>
<tr>
<td> Transposition of the great arteries</td>
<td>
</td>
</tr>
<tr>
<td> Double outlet right ventricle</td>
<td>
</td>
</tr>
<tr>
<td>Miscellaneous lesions</td>
<td>14 (17.1)</td>
</tr>
<tr>
<td> Mitral valve disease</td>
<td>
</td>
</tr>
<tr>
<td> Anomalous origin of the left coronary artery from the pulmonary artery</td>
<td>
</td>
</tr>
<tr>
<td> Anomalous coronary artery not otherwise specified</td>
<td>
</td>
</tr>
<tr>
<td> Ebstein anomaly of the tricuspid valve</td>
<td>
</td>
</tr>
<tr>
<td> Rings and slings</td>
<td>
</td>
</tr>
<tr>
<td> Dilated cardiomyopathy myocarditis</td>
<td>
</td>
</tr>
<tr>
<td> Idiopathic pulmonary hypertension</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-2150135113481042">
<p>Abbreviation: VSD, ventricular septal defect.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A total of 1,090 prescriptions were administered with a median of 13 prescriptions (IQR 9-16) per patient. Of all the prescribed drugs, 36% of the drugs used was off-label, with a median of four off-label drugs prescribed per patient (IQR 2-7), and 38 (46%) of 82 patients receiving more than four off-label drugs. In all, 94% of the patients received ≥1 drug off-label. The median ratio of off-label to total drugs received was 33% (IQR 20%-48%). Patients receiving more than four off-label medications were younger (median 3 vs 30 months, <italic>P</italic> &lt; .001), had a longer CICU LOS (median 9.5 vs 2 days, <italic>P</italic> &lt; .001) and increased ventilator days (median two vs one day, <italic>P</italic> &lt; .001) compared to those patients receiving less than four off-label medications. Receipt of vecuronium was associated with a longer CICU LOS (median seven vs two days; <italic>P</italic> &lt; .001). Vasoactives (40.2%) and analgesics (34.1%) were the most commonly prescribed classes of drugs that were off-label (<xref ref-type="table" rid="table3-2150135113481042">Table 3</xref>).</p>
<table-wrap id="table3-2150135113481042" position="float">
<label>Table 3.</label>
<caption>
<p>Frequency of Administration and Off-Label Drug Use.</p>
</caption>
<graphic alternate-form-of="table3-2150135113481042" xlink:href="10.1177_2150135113481042-table3.tif"/>
<table>
<thead>
<tr>
<th>Medication Category</th>
<th>Patients Receiving Drug, %</th>
<th>Patients Receiving Drug Off-Label, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>91.5</td>
<td>34.1</td>
</tr>
<tr>
<td>Diuretics</td>
<td>89.0</td>
<td>23.1</td>
</tr>
<tr>
<td>Antibiotics/antifungals</td>
<td>87.7</td>
<td>15.9</td>
</tr>
<tr>
<td>GI drugs</td>
<td>85.4</td>
<td>29.3</td>
</tr>
<tr>
<td>Anticoagulants/procoagulants/hemostatics</td>
<td>84.1</td>
<td>9.8</td>
</tr>
<tr>
<td>Vasoactives</td>
<td>69.5</td>
<td>40.2</td>
</tr>
<tr>
<td>Sedatives/anesthetics</td>
<td>65.9</td>
<td>14.6</td>
</tr>
<tr>
<td>Paralytics</td>
<td>32.9</td>
<td>14.6</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>31.7</td>
<td>25.6</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>28.1</td>
<td>2.4</td>
</tr>
<tr>
<td>Steroids</td>
<td>26.8</td>
<td>3.7</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>23.1</td>
<td>13.4</td>
</tr>
<tr>
<td>Endocrine drugs</td>
<td>11.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Other</td>
<td>11.0</td>
<td>2.4</td>
</tr>
<tr>
<td>β-Antagonists for heart failure</td>
<td>1.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-2150135113481042">
<p>Abbreviation: GI, gastrointestinal.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Of the 82 patients studied, 24 (29.3%) were neonates. The median number of total drugs per neonate was 14 (IQR 9-19.5), and the median number of off-label drugs used was 7.5 (IQR 4-10.5), with a median ratio of off-label to total drugs being 48% (IQR 43%-56%). Neonates were prescribed more off-label drugs than non-neonates (7.5 vs 3, <italic>P</italic> = .004) and had longer CICU LOS (median 8.5 vs 2 days, <italic>P</italic> &lt; .001) than older patients. Neonates had longer duration of mechanical ventilation (median three vs one day, <italic>P</italic> = .09) and an increased requirement for extracorporeal membrane oxygenation (4 (17%) of 24 vs 2 (3%) of 58, <italic>P</italic> = .06), although these results did not reach statistical significance.</p>
<p>Dopamine, which is not approved for use in children, is used frequently as first-line therapy in children with inadequate cardiac output.<sup>
<xref ref-type="bibr" rid="bibr7-2150135113481042">7</xref>,<xref ref-type="bibr" rid="bibr8-2150135113481042">8</xref>
</sup> Given the ubiquitous use of dopamine in most CICU’s, analyses were performed excluding dopamine to remove any potential confounding effects on off-label drug use and exposure. In all, 37 (45%) of the 82 patients received dopamine, all of whom also received at least one other medication off-label. Excluding dopamine did not change the median number of drugs prescribed off-label (median = 4), and the association between off-label drug use and LOS and duration of mechanical ventilation remained significant (<italic>P</italic> = .03 and <italic>P</italic> = .01, respectively).</p>
<p>We constructed a multivariate regression model on CICU LOS, which included patient’s age and number of off-label drugs prescribed. Adjusting for age, multivariate regression analysis demonstrated that for each additional off-label drug prescribed, CICU LOS increased by 1.49 days (<italic>P</italic> &lt; .001). Furthermore, when excluding dopamine and adjusting for age, each additional off-label drug prescribed was associated with an increased CICU LOS of 1.62 days (<italic>P</italic> &lt; .001). Variables included in our analysis are shown in <xref ref-type="table" rid="table4-2150135113481042">Table 4</xref>.</p>
<table-wrap id="table4-2150135113481042" position="float">
<label>Table 4.</label>
<caption>
<p>Multivariate Regression Models on CICU Length of Stay.</p>
</caption>
<graphic alternate-form-of="table4-2150135113481042" xlink:href="10.1177_2150135113481042-table4.tif"/>
<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>
<italic>P</italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Model including dopamine</td>
</tr>
<tr>
<td> Age</td>
<td>−0.0002</td>
<td>.49</td>
</tr>
<tr>
<td> Off-label medications</td>
<td>1.4861</td>
<td>&lt;.001</td>
</tr>
<tr>
<td colspan="3">Model excluding dopamine</td>
</tr>
<tr>
<td> Age</td>
<td>−0.0002</td>
<td>.54</td>
</tr>
<tr>
<td> Off-label medications</td>
<td>1.6173</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-2150135113481042">
<p>Abbreviation: CICU, cardiac intensive care unit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-2150135113481042">
<title>Discussion</title>
<p>To our knowledge, this is the first study on off-label drug use in a pediatric CICU population. Nearly, all patients in the pediatric CICU receive medications that are considered off-label for their age. Patients prescribed more than the median number of off-label drugs in our study were younger, had longer CICU lengths of stay, and an increased number of ventilator days. After adjusting for age, each additional off-label drug prescribed was associated with an increased LOS. Others have reported similar associations between off-label drug use and LOS,<sup>
<xref ref-type="bibr" rid="bibr4-2150135113481042">4</xref>
</sup> and described the use of off-label drugs in children with cardiac disease.<sup>
<xref ref-type="bibr" rid="bibr9-2150135113481042">9</xref>
</sup>
</p>
<p>In all, 36% of all drugs used in this study was off-label. Similar use of off-label drugs in pediatrics has been reported in several studies conducted in various hospitals and outpatient settings. Turner et al described 25% of all prescriptions as either unlicensed or off-label in general pediatric wards in the United Kingdom.<sup>
<xref ref-type="bibr" rid="bibr10-2150135113481042">10</xref>
</sup> A multicenter study of general pediatric wards found that 46% of all prescriptions were either unlicensed or off-label.<sup>
<xref ref-type="bibr" rid="bibr11-2150135113481042">11</xref>
</sup> Off-label use has also been described in neonatal ICUs,<sup>
<xref ref-type="bibr" rid="bibr5-2150135113481042">5</xref>,<xref ref-type="bibr" rid="bibr12-2150135113481042">12</xref>,<xref ref-type="bibr" rid="bibr13-2150135113481042">13</xref>
</sup> oncology department,<sup>
<xref ref-type="bibr" rid="bibr14-2150135113481042">14</xref>
</sup> cardiology ward,<sup>
<xref ref-type="bibr" rid="bibr15-2150135113481042">15</xref>
</sup> and outpatient setting.<sup>
<xref ref-type="bibr" rid="bibr16-2150135113481042">16</xref>
</sup>
</p>
<p>In our study, the most frequent off-label prescriptions were analgesics (oxycodone) and vasoactives (dopamine). Similar data have been reported in inpatient units<sup>
<xref ref-type="bibr" rid="bibr11-2150135113481042">11</xref>
</sup> and pediatric ICUs.<sup>
<xref ref-type="bibr" rid="bibr17-2150135113481042">17</xref>
</sup> However, the CICU is a unique population, because neonates comprise a large portion of the patients and frequently require analgesics and vasoactives. We have shown that neonates are exposed to a statistically significant greater number of off-label drugs and have longer lengths of stay compared to older children. These data are supported by multiple studies showing a high prevalence of off-label drug use in neonates.<sup>
<xref ref-type="bibr" rid="bibr5-2150135113481042">5</xref>,<xref ref-type="bibr" rid="bibr13-2150135113481042">13</xref>
</sup> Furthermore, surgical and medical advances now allow many low-birth weight neonates to undergo surgical procedures, and these patients have been shown to be a particularly vulnerable population with increased lengths of stay and mortality.<sup>
<xref ref-type="bibr" rid="bibr18-2150135113481042">18</xref>
</sup>
</p>
<p>Neonates have significant differences in drug pharmacokinetics and pharmacodynamics compared to adults and older children.<sup>
<xref ref-type="bibr" rid="bibr19-2150135113481042">19</xref>
</sup> The high level of off-label drug use in neonates highlights the limited number of studies performed in this patient population and the need for safety and efficacy trials. However, persistent barriers to conducting trials in this patient population persist despite the six-month patent extensions for drugs studied in children granted through the 1997 Pediatric Exclusivity Provision of United States Food and Drug Administration (<ext-link ext-link-type="uri" xlink:href="www.fda.gov/cder/pediatric">www.fda.gov/cder/pediatric</ext-link>). Of the top 10 most commonly prescribed drugs in this study (<xref ref-type="table" rid="table5-2150135113481042">Tables 5</xref> and <xref ref-type="table" rid="table6-2150135113481042">6</xref>), only 3 have been granted pediatric exclusivity (milrinone, fentanyl, and enalapril).</p>
<table-wrap id="table5-2150135113481042" position="float">
<label>Table 5.</label>
<caption>
<p>Ten Most Commonly Prescribed Off-Label Drugs.</p>
</caption>
<graphic alternate-form-of="table5-2150135113481042" xlink:href="10.1177_2150135113481042-table5.tif"/>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Number (%) of Prescriptions (n = 390)</th>
<th>Number (%) of Patients Receiving Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodone</td>
<td>43 (11.0)</td>
<td>43 (52)</td>
</tr>
<tr>
<td>Dopamine</td>
<td>37 (9.5)</td>
<td>35 (43)</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>37 (9.5)</td>
<td>37 (45)</td>
</tr>
<tr>
<td>Milrinone</td>
<td>37 (9.5)</td>
<td>36 (44)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>21 (5.4)</td>
<td>21 (26)</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>18 (4.6)</td>
<td>18 (22)</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>16 (4.1)</td>
<td>16 (20)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>14 (3.6)</td>
<td>14 (17)</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>12 (3.1)</td>
<td>8 (10)</td>
</tr>
<tr>
<td>Enalapril</td>
<td>10 (2.6)</td>
<td>10 (12)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table6-2150135113481042" position="float">
<label>Table 6.</label>
<caption>
<p>Ten Most Commonly Prescribed Drugs in the CICU.</p>
</caption>
<graphic alternate-form-of="table6-2150135113481042" xlink:href="10.1177_2150135113481042-table6.tif"/>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Number (%) of Prescriptions (n = 1090)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>73 (6.7)</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>66 (6.1)</td>
</tr>
<tr>
<td>Heparin</td>
<td>64 (5.9)</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>63 (5.8)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>54 (5.0)</td>
</tr>
<tr>
<td>Morphine</td>
<td>53 (4.9)</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>51 (4.7)</td>
</tr>
<tr>
<td>Midazolam</td>
<td>47 (4.3)</td>
</tr>
<tr>
<td>Oxcodone</td>
<td>43 (4.9</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>38 (3.5)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-2150135113481042">
<p>Abbreviation: CICU, cardiac intensive care unit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Although milrinone, fentanyl, and enalapril have been granted exclusivity and have been evaluated in safety and efficacy trials, all three remain unlabeled for pediatric patients. In a randomized, double-blind, placebo-controlled trial, Hoffman et al demonstrated the safety and efficacy of milrinone in reducing the risk of low-cardiac output syndrome after pediatric congenital heart surgery.<sup>
<xref ref-type="bibr" rid="bibr20-2150135113481042">20</xref>
</sup> The pharmacokinetics of milrinone has also been studied in neonates providing additional information about appropriate pediatric dosing.<sup>
<xref ref-type="bibr" rid="bibr21-2150135113481042">21</xref>
</sup> Fentanyl has been studied in infants undergoing surgical repair of congenital heart defects and found to be safe and effective for cardiac surgery in infants.<sup>
<xref ref-type="bibr" rid="bibr22-2150135113481042">22</xref>
</sup> In a multicenter randomized controlled trial of enalapril in infants with single-ventricle palliations, investigators did not demonstrate any difference in adverse events between the enalapril and the placebo groups.<sup>
<xref ref-type="bibr" rid="bibr23-2150135113481042">23</xref>
</sup> Schaefer et al also found that enalapril is safe and effective in reducing blood pressure in hypertensive children.<sup>
<xref ref-type="bibr" rid="bibr24-2150135113481042">24</xref>
</sup> Despite the favorable outcomes of these studies, none of the above medications have been approved for use in pediatric patients.</p>
<p>Although several of the drugs being used off-label show favorable outcomes in safety and efficacy studies, other off-label drugs have been shown to be particularly detrimental in the pediatric population. For example, recovery of neuromuscular function after discontinuation of neuromuscular blocking drug infusion in children was shown to be significantly faster with cisatracurium than vecuronium in a randomized controlled trial done by Burmester and Mok.<sup>
<xref ref-type="bibr" rid="bibr25-2150135113481042">25</xref>
</sup> We found that receipt of vecuronium was associated with a longer CICU LOS (median seven vs two days; <italic>P</italic> &lt; .001). Increased CICU LOS may be related to the patient population who receives these drugs, typically sicker patients, and could also be related to neuromuscular ICU weakness, but additional studies are needed to determine this association. Currently, vecuronium, as well as other muscle relaxants, continues to be used off-label with potential for adverse effects.</p>
<sec id="section8-2150135113481042">
<title>Limitations</title>
<p>The low mortality rate during the study period limited our ability to make an association between mortality rate and off-label drug use. Further, our limited number of patients does not allow for the correlation of severity of illness with off-label drug use. In order to best assess the relationship between off-label drug use and mortality, comprehensive patient specific data including risk-adjusted mortality indicators would be necessary to carry out reliable multivariate analysis, which was not within the scope of this work. Our study represents experience from a single center and therefore may not be reflective of clinical practice in CICU’s at large. Larger studies are needed to determine broader applicability and the full impact of off-label drug use on this high-risk pediatric population.</p>
</sec>
</sec>
<sec id="section9-2150135113481042">
<title>Conclusions</title>
<p>Off-label drug use in pediatric cardiac critical care occurs at a high rate. The frequency of use is likely higher in patients with a higher severity of illness; however, additional work is needed to elucidate this relationship more clearly. Further safety, efficacy, and pharmaceutical trials are warranted to optimize the use of these drugs to improve outcomes, particularly in high-risk pediatric populations.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn4-2150135113481042">
<p>Presented at the 2009 American Academy of Pediatrics (AAP) National Conference and Exhibition, Washington, DC; October 17-20, 2009.</p>
</fn>
<fn fn-type="other" id="fn1-2150135113481042">
<label>Authors’ Note</label>
<p>This study was performed at Children’s National Medical Center, 111 Michigan Ave, Washington, DC 20010, USA.</p>
</fn>
<fn fn-type="conflict" id="fn2-2150135113481042">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-2150135113481042">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2150135113481042">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marelli</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Ionescu-Ittu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rahme</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pilote</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Congenital heart disease in the general population: changing prevalence and age distribution</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr2-2150135113481042">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilboa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Salemi</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Nembhard</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Fixler</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>(<issue>22</issue>):<fpage>2254</fpage>–<lpage>2263</lpage>.</citation>
</ref>
<ref id="bibr3-2150135113481042">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khairy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ionescu-Ittu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Abrahamowicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pilote</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marelli</surname>
<given-names>AJ.</given-names>
</name>
</person-group> <article-title>Changing mortality in congenital heart disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>14</issue>):<fpage>1149</fpage>–<lpage>1157</lpage>.</citation>
</ref>
<ref id="bibr4-2150135113481042">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>DM</given-names>
</name>
<etal/>
</person-group> <article-title>Off-label drug use in hospitalized children</article-title>. <source>Arch Pediatr Adolesc Med</source>. <year>2007</year>;<volume>161</volume>(<issue>3</issue>):<fpage>282</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr5-2150135113481042">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Donnell</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>CJ.</given-names>
</name>
</person-group> <article-title>Unlicensed and off-label drug use in an Australian neonatal intensive care unit</article-title>. <source>Pediatrics</source>. <year>2002</year>;<volume>110</volume>(<issue>5</issue>):<fpage>e52</fpage>.</citation>
</ref>
<ref id="bibr6-2150135113481042">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popernack</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Lucking</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>Decreasing unplanned extubations: utilization of the Penn state children's hospital sedation algorithm</article-title>. <source>Pediatr Crit Care</source> <source>Med</source>. <year>2004</year>;<volume>5</volume>(<issue>1</issue>):<fpage>58</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr7-2150135113481042">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Oliveira</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Ashburn</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Khalid</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevention of early sudden circulatory collapse after the Norwood operation</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>(<issue>11 suppl 1</issue>):<fpage>II133</fpage>–<lpage>II138</lpage>.</citation>
</ref>
<ref id="bibr8-2150135113481042">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dellinger</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Carlet</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group> <article-title>Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>(<issue>1</issue>):<fpage>296</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr9-2150135113481042">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasquali</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Slonim</surname>
<given-names>AD</given-names>
</name>
<etal/>
</person-group> <article-title>Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2008</year>;<volume>1</volume>(<issue>2</issue>):<fpage>74</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr10-2150135113481042">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Longworth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nunn</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Choonara</surname>
<given-names>I.</given-names>
</name>
</person-group> <article-title>Unlicensed and off label drug use in paediatric wards: prospective study</article-title>. <source>BMJ</source>. <year>1998</year>;<volume>316</volume>(<issue>7128</issue>):<fpage>343</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr11-2150135113481042">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Choonara</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Impicciatore</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>320</volume>(<issue>7227</issue>):<fpage>79</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr12-2150135113481042">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choonara</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Unlicensed and off label drug use in neonates</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>1999</year>;<volume>80</volume>(<issue>2</issue>):<fpage>F142</fpage>–<lpage>F144</lpage>.</citation>
</ref>
<ref id="bibr13-2150135113481042">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The use of unlicensed and off-label medicines in the neonate</article-title>. <source>Semin Fetal Neonatal Med</source>. <year>2005</year>;<volume>10</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr14-2150135113481042">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gudka</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children</article-title>. <source>Ann Oncol</source>. <year>2003</year>;<volume>14</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr15-2150135113481042">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajcetic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jelisavcic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mitrovic</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Off label and unlicensed drugs use in paediatric cardiology</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2005</year>;<volume>61</volume>(<issue>10</issue>):<fpage>775</fpage>–<lpage>779</lpage>.</citation>
</ref>
<ref id="bibr16-2150135113481042">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazzano</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Mangione-Smith</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schonlau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suttorp</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Brook</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Off-label prescribing to children in the United States outpatient setting</article-title>. <source>Acad Pediatr</source>. <year>2009</year>;<volume>9</volume>(<issue>2</issue>):<fpage>81</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr17-2150135113481042">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brazelton</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Off-label medication use in an academic hospital pediatric critical care unit</article-title>. <source>WMJ</source>. <year>2009</year>;<volume>108</volume>(<issue>7</issue>):<fpage>343</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr18-2150135113481042">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curzon</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Milford-Beland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group> <article-title>Cardiac surgery in infants with low birth weight is associated with increased mortality: analysis of the society of thoracic surgeons congenital heart database</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2008</year>;<volume>135</volume>(<issue>3</issue>):<fpage>546</fpage>–<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr19-2150135113481042">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allegaert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Verbesselt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Naulaers</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Developmental pharmacology: neonates are not just small adults</article-title>. <source>Acta Clin Belg</source>. <year>2008</year>;<volume>63</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr20-2150135113481042">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Wernovsky</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Atz</surname>
<given-names>AM</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>7</issue>):<fpage>996</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr21-2150135113481042">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuppa</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Nicolson</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>PC</given-names>
</name>
<etal/>
</person-group> <article-title>Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction</article-title>. <source>Anesth Analg</source>. <year>2006</year>;<volume>102</volume>(<issue>4</issue>):<fpage>1062</fpage>–<lpage>1069</lpage>.</citation>
</ref>
<ref id="bibr22-2150135113481042">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hickey</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>DD</given-names>
</name>
</person-group>. <article-title>Fentanyl- and sufentanil-oxygen-pancuronium anesthesia for cardiac surgery in infants</article-title>. <source>Anesth Analg</source>. <year>1984</year>;<volume>63</volume>(<issue>2</issue>):<fpage>117</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr23-2150135113481042">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mahony</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Enalapril in infants with single ventricle: results of a multicenter randomized trial</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>(<issue>4</issue>):<fpage>333</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr24-2150135113481042">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Litwin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zachwieja</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study</article-title>. <source>J Hypertens</source>. <year>2011</year>;<volume>29</volume>(<issue>12</issue>):<fpage>2484</fpage>–<lpage>2490</lpage>.</citation>
</ref>
<ref id="bibr25-2150135113481042">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burmester</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>Q</given-names>
</name>
</person-group>. <article-title>Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit</article-title>. <source>Intensive Care Med</source>. <year>2005</year>;<volume>31</volume>(<issue>5</issue>):<fpage>686</fpage>–<lpage>692</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>